MYGN MYRIAD GENETICS INC
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 899923 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-2.6%
TTM net income YoY67.8%
TTM EPS YoY69.0%
Revenue 3-yr CAGR3.0%
Net income 3-yr CAGR—
Margins
Gross margin68.3%
Operating margin-14.3%
Net margin-16.1%
FCF margin—
EBITDA margin-10.0%
Returns
ROE-40.2%
ROA-19.3%
ROIC (approx.)-28.9%
Asset turnover1.20x
Leverage & solvency
Liabilities / assets55.8%
Debt / equity0.45x
Current ratio1.98x
Interest coverage-6.90x
Cash quality & payout
Operating cash flow / net income0.15x
Accruals ratio-16.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $202.70M | $190.70M | $200.40M | $209.80M | $205.70M | $213.10M | $195.90M | $210.60M |
| Cost of revenue | $65.00M | $63.70M | $62.80M | $63.00M | $61.90M | $61.30M | $61.70M | $59.70M |
| Gross profit | $137.70M | $127.00M | $137.60M | $146.80M | $143.80M | $151.80M | $134.20M | $150.90M |
| R&D expense | $26.50M | $25.00M | $27.10M | $25.50M | $28.20M | $25.60M | $27.50M | $32.20M |
| SG&A expense | $67.20M | $57.80M | $62.20M | $55.60M | $67.90M | $66.80M | $66.50M | -$148.10M |
| Operating income | -$39.90M | -$38.90M | -$30.70M | -$5.70M | -$23.30M | -$329.20M | -$29.00M | -$39.00M |
| Interest expense | $4.10M | $4.10M | $4.10M | $4.40M | $3.80M | $1.50M | $800,000 | $700,000 |
| Pretax income | -$43.60M | -$42.60M | -$34.10M | -$8.90M | -$26.20M | -$330.60M | -$29.40M | -$39.10M |
| Income tax | $300,000 | $600,000 | $0 | -$1.00M | $1.20M | -$100,000 | -$29.30M | $3.40M |
| Net income | -$43.90M | -$43.20M | -$34.10M | -$7.90M | -$27.40M | -$330.50M | -$100,000 | -$42.50M |
| EBITDA | -$35.00M | -$34.10M | -$18.20M | $6.90M | -$18.50M | -$324.30M | -$14.60M | -$24.20M |
| EPS (basic) | -0.46 | -0.46 | -0.36 | — | -0.29 | -3.57 | 0.00 | — |
| EPS (diluted) | -0.46 | -0.46 | -0.36 | — | -0.29 | -3.57 | 0.00 | — |
| Weighted avg. shares (diluted) | 95.70M | 94.80M | 93.70M | — | 93.10M | 92.50M | 91.40M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $107.10M | $115.20M | $124.40M | $149.60M | $145.40M | $74.40M | $91.80M | $111.90M |
| Short-term investments | — | — | — | — | — | — | — | $0 |
| Receivables | $105.50M | $109.50M | $123.80M | $115.30M | $118.00M | $137.00M | $120.40M | $121.20M |
| Inventory | $28.60M | $30.60M | $27.90M | $30.60M | $31.60M | $28.70M | $28.30M | $27.50M |
| Current assets | $271.90M | $289.00M | $312.80M | $332.60M | $344.80M | $284.30M | $287.20M | $298.00M |
| PP&E, net | $104.70M | $108.90M | $111.50M | $114.00M | $111.40M | $113.00M | $114.00M | $117.40M |
| Goodwill | $47.10M | $47.10M | $47.10M | $51.60M | $51.60M | $51.60M | $286.30M | $286.30M |
| Intangibles | $131.80M | $139.00M | $145.70M | $153.40M | $163.10M | $170.10M | $257.50M | $262.40M |
| Total assets | $609.20M | $638.90M | $673.70M | $706.60M | $728.10M | $677.30M | $1.01B | $1.03B |
| Current liabilities | $137.60M | $130.70M | $130.20M | $133.80M | $148.00M | $199.90M | $151.10M | $164.10M |
| Short-term debt | — | — | — | — | — | $59.40M | — | $0 |
| Long-term debt | $121.10M | $120.70M | $120.30M | $119.90M | $119.50M | $0 | $59.30M | $39.60M |
| Total debt | $121.10M | $120.70M | $120.30M | $119.90M | $119.50M | $59.40M | $59.30M | $39.60M |
| Total liabilities | $340.20M | $335.00M | $336.30M | $338.60M | $355.30M | $289.20M | $301.20M | $326.50M |
| Shareholders' equity | $269.00M | $303.90M | $337.40M | $368.00M | $372.80M | $388.10M | $704.90M | $701.10M |
| Net debt | $14.00M | $5.50M | -$4.10M | -$29.70M | -$25.90M | -$15.00M | -$32.50M | -$72.30M |
| Shares outstanding | 95.70M | 95.60M | 94.40M | 93.50M | 93.10M | 93.10M | 92.20M | 91.30M |
| Cash flow statement | ||||||||
| Operating cash flow | -$6.50M | -$8.30M | -$15.70M | $10.60M | $21.10M | -$13.60M | -$16.30M | $6.60M |
| Investing cash flow | -$2.10M | -$3.20M | -$6.50M | -$6.00M | -$6.20M | -$6.90M | -$8.30M | -$5.90M |
| Financing cash flow | -$300,000 | $2.20M | -$3.00M | -$8.20M | $56.20M | $2.60M | $13.60M | $2.10M |
| Depreciation & amortization | $4.90M | $4.80M | $12.50M | $12.60M | $4.80M | $4.90M | $14.40M | $14.80M |
| Stock-based compensation | $9.20M | $7.20M | $6.50M | $2.80M | $12.20M | $10.70M | $9.50M | $10.90M |
Free plan shows the latest 8 periods; Pro shows all 69 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.